ProCE Banner Activity

Enhancing Care in Moderate to Severe Psoriasis: Treatment Selection, Medication Adherence, and Healthcare Disparities

Slideset Download

Download these slides for an expert review of novel therapies, improved adherence, and reducing health disparities in the management of moderate to severe psoriasis.

Released: September 09, 2022

Expiration: September 08, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Steven Feldman

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Melodie S. Young

Melodie S. Young, MSN, RN, ANP-C

Nurse Practitioner
Mindful Dermatology and Modern Research Associates
Dallas, Texas

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun, UCB, vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.

Melodie S. Young, MSN, RN, ANP-C

Nurse Practitioner
Mindful Dermatology and Modern Research Associates
Dallas, Texas

Melodie S. Young, MSN, RN, ANP-C: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Janssen, Leo, Lilly, Novartis, UCB.